Copertina

Effect of Cladribine Tablets on the Pharmacokinetics of a Combined Oral Contraceptive in Pre‐Menopausal Women With Relapsing Multiple Sclerosis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Robert Hermann, Kerstin Hellwig, Sumedh Gaikwad, Andrew Galazka, Afrim Bytyqi, Dominic Jack, Axel Krebs‐Brown, Claudia Vetter, Axel Nolting, Karthik Venkatakrishnan, Jennifer Q. Dong
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Clinical and Translational Science
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
di: Ralf Gold, et al.
Pubblicazione: (2026)

Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis
di: Ludwig Kappos, et al.
Pubblicazione: (2025)

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma
di: Junyi Li, et al.
Pubblicazione: (2025)

Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T‐Cell Lymphoma
di: Theingi M. Thway, et al.
Pubblicazione: (2025)

Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling of Serum M‐Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma
di: Cheryl Li, et al.
Pubblicazione: (2025)

Bioequivalence of Aripiprazole Oral Soluble Films and Orally Disintegrating Tablets in Healthy Participants: A Crossover Study
di: Ruoming Li, et al.
Pubblicazione: (2025)

Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive NMOSD
di: Sean J. Pittock, et al.
Pubblicazione: (2026)

Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions
di: Min Xiao, et al.
Pubblicazione: (2025)

Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach
di: Sonia Khier, et al.
Pubblicazione: (2026)

A Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women
di: Jacqueline Gerhart, et al.
Pubblicazione: (2026)

Pharmacokinetics as a Biomarker
di: John A. Wagner, et al.
Pubblicazione: (2026)

Predicting Pharmacokinetics in Rats Using Machine Learning: A Comparative Study Between Empirical, Compartmental, and PBPK ‐Based Approaches
di: Moritz Walter, et al.
Pubblicazione: (2025)

Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial
di: Andrew Leber, et al.
Pubblicazione: (2025)

Real‐Life Safety of Japanese Cedar Pollen Sublingual Immunotherapy Tablets: A Post‐Marketing Survey
di: Minoru Gotoh, et al.
Pubblicazione: (2026)

The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications
di: Virginia D. Schmith, et al.
Pubblicazione: (2026)

Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
di: Andy Sykes, et al.
Pubblicazione: (2026)

Asia‐inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler
di: Hong Lu, et al.
Pubblicazione: (2024)

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis
di: Alexandra Garcia, et al.
Pubblicazione: (2025)

Network Localization of Fatigue in Multiple Sclerosis
di: Olli Likitalo, et al.
Pubblicazione: (2025)

Pharmacokinetic‐Pharmacodynamic Model of Paclitaxel‐Induced Peripheral Neuropathy
di: Yuchen Sun, et al.
Pubblicazione: (2025)

Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers
di: Jumar Etkins, et al.
Pubblicazione: (2025)

Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment
di: Olivier Schueller, et al.
Pubblicazione: (2025)

Frailty Exacerbates Disability in Progressive Multiple Sclerosis
di: Taylor R. Wicks, et al.
Pubblicazione: (2025)

Correction to “Genotype‐Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers”
Pubblicazione: (2026)

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis
di: Methma Udawatta, et al.
Pubblicazione: (2025)

Claustrum Volume Is Reduced in Multiple Sclerosis and Predicts Disability
di: Nicole Shelley, et al.
Pubblicazione: (2025)

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
di: F. Shawket, et al.
Pubblicazione: (2026)

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis
di: Ngoc Hoa Truong, et al.
Pubblicazione: (2025)

Real‐World Impact of Amiodarone on Apixaban Population Pharmacokinetics in Hospitalized Patients
di: Samantha Kolowrat, et al.
Pubblicazione: (2025)

Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome
di: Kevin Lam, et al.
Pubblicazione: (2025)

Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis
di: Cindy X. Zhang, et al.
Pubblicazione: (2025)

Hemodynamic and Pharmacokinetic Interactions of TPN171 with Alcohol in Healthy Male Subjects
di: Jie Cheng, et al.
Pubblicazione: (2025)

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis
di: Kimberly H. Markowitz, et al.
Pubblicazione: (2026)

Insulin and Metformin are Associated With Reduced Risk of Amyotrophic Lateral Sclerosis
di: Steven Lehrer, et al.
Pubblicazione: (2024)

Sex Hormones Associate With Amyotrophic Lateral Sclerosis Risk and Survival
di: Stephen A. Goutman, et al.
Pubblicazione: (2025)

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers
di: Bhagwat Prasad
Pubblicazione: (2026)

Predicting the Pharmacokinetics of T‐Cell Engagers as a Function of Target‐Mediated Drug Disposition
di: Mark Penney, et al.
Pubblicazione: (2025)

Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics
di: Hui Yu, et al.
Pubblicazione: (2025)

Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
di: Huijun Chen, et al.
Pubblicazione: (2024)

Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis
di: Atul Rawal, et al.
Pubblicazione: (2025)